Pharmacogenomic assessment of Mexican and Peruvian populations.


BACKGROUND Clinically relevant polymorphisms often demonstrate population-specific allele frequencies. Central and South America remain largely uncategorized in the context of pharmacogenomics. MATERIALS & METHODS We assessed 15 polymorphisms from 12 genes (ABCB1 3435C>T, ABCG2 Q141K, CYP1B1*3, CYP2C19*2, CYP3A4*1B, CYP3A5*3C, ERCC1 N118N, ERCC2 K751Q, GSTP1 I105V, TPMT 238G>C, TPMT 460G>A, TPMT 719A>G, TYMS TSER, UGT1A1*28 and UGT1A1 -3156G>A) in 81 Peruvian and 95 Mexican individuals. RESULTS Six polymorphism frequencies differed significantly between the two populations: ABCB1 3435C>T, CYP1B1*3, GSTP1 I105V, TPMT 460G>A, UGT1A1*28 and UGT1A1 -3156G>A. The pattern of observed allele frequencies for all polymorphisms could not be accurately estimated from any single previously studied population. CONCLUSION This highlights the need to expand the scope of geographic data for use in pharmacogenomics studies.

DOI: 10.2217/pgs.15.10


Citations per Year

160 Citations

Semantic Scholar estimates that this publication has 160 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Marsh2015PharmacogenomicAO, title={Pharmacogenomic assessment of Mexican and Peruvian populations.}, author={Sharon Marsh and Cristi R. King and Derek J. Van Booven and Jane Yen Revollo and Robert H. Gilman and Howard L. McLeod}, journal={Pharmacogenomics}, year={2015}, volume={16 5}, pages={441-8} }